(Q37159492)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Bruce J Giantonio

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

683-688

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18471041%20AND%20SRC:MED&resulttype=core&format=json

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics-->mechanism(s) of interaction).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.5.683